Effect of amphotericin B lipid formulation on immune response in aspergillosis

被引:11
|
作者
Saxena, S
Bhatnagar, PK
Ghosh, PC
Sarma, PU
机构
[1] Ctr Biochem Technol, Delhi 7, India
[2] Univ Delhi, Dept Biochem, New Delhi 21, India
关键词
Aspergillus fumigatus; immuneregulation; amphotericin B; sterol vesicles; cytokines; lesions;
D O I
10.1016/S0378-5173(99)00200-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The immune response against Aspergillus fumigatus has been studied during infection and therapy in order to understand the mechanism of pathogenesis and the effect of treatment with amphotericin B. With this in view an animal model of aspergillosis was developed in Balb/c mice by intravenous injection of an optimized dose of 3.6 x 10(6) A. fumigatus spores. Infection due to Aspergillus was well established by histopathological examination and fungal load in the animal. Lesions and eosinophil infiltration was observed in the infected tissues which indicated the involvement of a Type I hypersensitivity response. Evaluation of serological parameters indicated high levels of interleukin-4 (IL-4) and A. fumigatus specific IgG antibodies. The reduction in fungal load and modulation of immune response in the infected mice was studied following treatment with amphotericin B/cholesterol hemisuccinate Vesicles (ABCV). The results clearly indicated significant reduction in the fungal load, disappearance of eosinophils and lesions with the appearance of macrophages and neutrophils in the infected lung tissue, a decrease in IL-4 (fourfold) and a concomitant increase of interferon-gamma (IFN-gamma; twofold) with an improvement in general condition of mice. In the non-treated mice, the rise of IL-4 level indicated the association of T(H)2 cell response with susceptibility to infection while the increase of IFN-gamma in the treated group suggested that T(H)1 cell response may be involved in resistance to Aspergillus infection. (C) 1999 Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:19 / 30
页数:12
相关论文
共 50 条
  • [31] CASE OF ASPERGILLOSIS TREATED WITH AMPHOTERICIN-B
    PEER, ET
    DISEASES OF THE CHEST, 1960, 38 (02): : 222 - 230
  • [32] Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical-control comparison with amphotericin
    Hiemenz, JW
    Lister, J
    Anaissie, EJ
    White, MH
    Dinubile, M
    Silber, J
    Horwith, G
    Lee, LW
    BLOOD, 1995, 86 (10) : 3383 - 3383
  • [33] Blastomycosis and histoplasmosis: Early response to amphotericin B lipid complex
    Baddour, LM
    INFECTIONS IN MEDICINE, 2002, 19 (03) : 119 - 121
  • [34] The effect of amphotericin B derivatives on Leishmania and immune functions
    Ehrenfreund-Kleinman, T
    Domb, AJ
    Jaffe, CL
    Nasereddin, A
    Leshem, B
    Golenser, J
    JOURNAL OF PARASITOLOGY, 2005, 91 (01) : 158 - 163
  • [35] Lipid formulations of amphotericin B
    AlAbdely, H
    Revankar, S
    Graybill, JR
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 18 (03) : 289 - 299
  • [36] Lipid formulations of amphotericin B
    Hiemenz, JW
    Walsh, TJ
    JOURNAL OF LIPOSOME RESEARCH, 1998, 8 (04) : 443 - 467
  • [37] Amphotericin B lipid complex
    Rapp, RP
    Gubbins, PO
    Evans, ME
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (10) : 1174 - 1186
  • [38] Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis
    Ruijgrok, EJ
    Fens, MHAM
    Bakker-Woudenberg, IAJM
    van Etten, EWM
    Vulto, AG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) : 1852 - 1854
  • [39] Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis
    Sionov, Edward
    Mendlovic, Sonia
    Segal, Esther
    JOURNAL OF INFECTION, 2006, 53 (02) : 131 - 139
  • [40] The lipid formulations of amphotericin B
    Herbrecht, R
    Natarajan-Amé, S
    Nivoix, Y
    Letscher-Bru, V
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (08) : 1277 - 1287